


AG-CR1-3565

14-Oct-2011

Troglitazone

[5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; Romglizone; BRN 4338399; CS-045; CI-991; GR 92132X]

| | |
|------------------|---|
| AG-CR1-3565-M005 | 5 mg |
| AG-CR1-3565-M025 | 25 mg |
| Formula | C ₂₄ H ₂₇ NO ₅ S |
| MW | 441.5 |
| CAS | 97322-87-7 |
| Merck Index | 14: 9769 |
| RTECS | XJ5813130 |



Handling / Storage

| | |
|--------------------|---------|
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |

Protect from light.

Use / Stability

Stable for at least 2 years after receipt when stored at -20°C.

MSDS available at www.adipogen.com or upon request.

Product Specifications

| | |
|------------|--|
| Purity | ≥98% |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO, ethanol or dimethylformamide (DMF). |

Product Description

- Potent and selective PPAR γ agonist with no activation of PPAR α and PPAR δ [2].
- Anti-diabetic agent with potent glucose-lowering effects and decreasing insulin resistance in adipose tissues. Stimulates adipogenesis [1, 6, 8].
- Apoptosis and cell cycle arrest inducer in several cancer cell lines [3-8].
- Anti-inflammatory [8-10, 12].
- Inhibits vascular smooth muscle cell (VSMC) migration [11].

WARNING: Intended for research use only. This product is not intended or approved for human, diagnostics, therapeutic or veterinary use. Use of this product for human or animal testing is extremely hazardous and may result in disease, severe injury, or death. **MATERIAL SAFETY DATA:** Review the complete Material Safety Data Sheet before use.

Adipogen AG
Schützenstrasse 12
4410 Liestal
Switzerland
TEL +41-61-926-60-40
FAX +41-61-926-60-49
info@adipogen.com

Adipogen Corp.
11588 Sorrento Valley Road, Suite 16
San Diego CA 92121-1336
USA
TEL (858) 457-8383
FAX (858) 457-8484
info-us@adipogen.com

Adipogen, Inc.
Room 401, Venture Building B, Songdo TechnoPark,
7-50 Sondo-dong, Yeonsu-gu, Incheon, 406-840,
South Korea
TEL 032-858-1470
FAX 032-831-1470
info@adipogen.com

For Local Distributors please visit
www.adipogen.com

Product Specific References

1. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats: T. Fujiwara, et al.; *Diabetes* **37**, 1549 (1988)
2. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma): J.M. Lehmann, et al.; *J. Biol. Chem.* **270**, 12953 (1995)
3. Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids: H. Asou, et al.; *Int. J. Oncol.* **15**, 1027 (1999)
4. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators: Y. Kodera, et al.; *J. Biol. Chem.* **275**, 33201 (2000)
5. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis: Y. Tsubouchi, et al.; *BBRC* **270**, 400 (2000)
6. Troglitazone and related compounds: therapeutic potential beyond diabetes: T. Fujiwara & H. Horikoshi; *Life Sci.* **67**, 2405 (2000)
7. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells: T. Okura, et al.; *Eur. J. Pharmacol.* **407**, 227 (2000)
8. Troglitazone and related compounds: therapeutic potential beyond diabetes: T. Fujiwara & H. Horikoshi; *Life Sci.* **67**, 2405 (2000) (Review)
9. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese: H. Ghanim, et al.; *J. Clin. Endocrinol. Metab.* **86**, 1306 (2001)
10. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: A. Aljada, et al.; evidence of an antiinflammatory action?: *J. Clin. Endocrinol. Metab.* **86**, 3250 (2001)
11. Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration: S. Goetze, et al.; *J. Cardiovasc. Pharmacol.* **38**, 909 (2001)
12. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300: K. Subbaramaiah, et al.; *J. Biol. Chem.* **276**, 12440 (2001)

WARNING: Intended for research use only. This product is not intended or approved for human, diagnostics, therapeutic or veterinary use. Use of this product for human or animal testing is extremely hazardous and may result in disease, severe injury, or death. **MATERIAL SAFETY DATA:** Review the complete Material Safety Data Sheet before use.

Adipogen AG
Schützenstrasse 12
4410 Liestal
Switzerland
TEL +41-61-926-60-40
FAX +41-61-926-60-49
info@adipogen.com

Adipogen Corp.
11588 Sorrento Valley Road, Suite 16
San Diego CA 92121-1336
USA
TEL (858) 457-8383
FAX (858) 457-8484
info-us@adipogen.com

Adipogen, Inc.
Room 401, Venture Building B, Songdo TechnoPark,
7-50 Sondo-dong, Yeonsu-gu, Incheon, 406-840,
South Korea
TEL 032-858-1470
FAX 032-831-1470
info@adipogen.com

For Local Distributors please visit
www.adipogen.com